Thrombotic Coronary Occlusion and Reperfusion: Unraveling the Determinants

Robert F Storey; William A E Parker

doi:10.1016/j.jacc.2023.03.391

Thrombotic Coronary Occlusion and Reperfusion: Unraveling the Determinants

J Am Coll Cardiol. 2023 May 16;81(19):1933-1936. doi: 10.1016/j.jacc.2023.03.391.

Authors

Robert F Storey¹, William A E Parker²

Affiliations

¹ Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom; South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom. Electronic address: r.f.storey@sheffield.ac.uk.
² Cardiovascular Research Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom; South Yorkshire Cardiothoracic Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

PMID: 37164526
DOI: 10.1016/j.jacc.2023.03.391

No abstract available

Keywords: ST-segment elevation myocardial infarction, thrombin; anticoagulant drugs; aspirin; fibrin; heparin; platelet aggregation inhibitors; platelets; thrombin-activatable fibrinolysis inhibitor.

Publication types

Editorial
Comment

MeSH terms

Coronary Occlusion* / diagnosis
Coronary Occlusion* / surgery
Heparin
Humans
Platelet Aggregation Inhibitors
Reperfusion

Substances

Heparin
Platelet Aggregation Inhibitors